Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.

S'inscrire

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

All sales are to be made pursuant to a previously signed/adopted 10b5-1 selling plan dated August 28, 2023 and all representations regarding non-public information were made as of the adoption of the plan.

Date of Notice

09/03/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

08/28/2023

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

Peter Virsik

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

ESSA Pharma (NASDAQ:EPIX)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024

Plus de graphiques de la Bourse ESSA Pharma

ESSA Pharma (NASDAQ:EPIX)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024

Plus de graphiques de la Bourse ESSA Pharma

Actualités ESSA Pharma Inc

Form 8-K - Current report
Mardi 17 Décembre 2024 ( il y a 1 semaine) • Edgar (US Regulatory)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mardi 17 Décembre 2024 ( il y a 1 semaine) • Edgar (US Regulatory)

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024
Mardi 17 Décembre 2024 ( il y a 1 semaine) • PR Newswire (US)

Form 8-K - Current report
Vendredi 6 Décembre 2024 ( il y a 3 semaines) • Edgar (US Regulatory)

Form 8-K - Current report
Vendredi 1 Novembre 2024 ( il y a 2 mois) • Edgar (US Regulatory)

ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Vendredi 1 Novembre 2024 ( il y a 2 mois) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Lundi 7 Octobre 2024 ( il y a 3 mois) • Edgar (US Regulatory)

ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress
Vendredi 13 Septembre 2024 ( il y a 3 mois) • PR Newswire (Canada)

ESSA Pharma to Present at the 2024 Cantor Global Healthcare Conference
Mercredi 11 Septembre 2024 ( il y a 3 mois) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Lundi 9 Septembre 2024 ( il y a 4 mois) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mercredi 4 Septembre 2024 ( il y a 4 mois) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Mardi 3 Septembre 2024 ( il y a 4 mois) • Edgar (US Regulatory)

Plus d'articles sur ESSA Pharma Inc

BNP Paribas Theam S&P 50...

DB X-Trackers MSCI Canad...

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales